by The Relapsed or Refractory Diffuse Large B-cell Lymphoma market is gaining traction due to emerging treatment options. Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin’s lymphoma, arising from B cells that have undergone malignant transformation. While the standard first-line therapy of rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is effective in around 60-70% of patients, a significant proportion of cases relapse or prove refractory to initial treatment.
The Global Relapsed or Refractory Diffuse Large B-cell Lymphoma Market is estimated to be valued at US$ 1777.75 Bn in 2024 and is expected to exhibit a CAGR of 16% over the forecast period 2024 To 2031. Key Takeaways
Key players operating in the Relapsed or Refractory Diffuse Large B-cell Lymphoma are Sharp Corp., LG, Samsung, Hitachi, and Panasonic. Monoclonal antibodies targeting CD20 such as obinutuzumab and ofatumumab have been approved for relapsed/refractory DLBCL and are being widely adopted.
The growing incidence of lymphoma and increasing R&D investments from key players are fueling the Relapsed or Refractory Diffuse Large B-cell Lymphoma Market Demand. According to Globocan 2020, lymphoma incidence has increased by nearly 57% from 1990 to 2020 globally.
Growing awareness and access to advanced treatment options are helping the market to expand globally. Approval of newer target therapies and immunotherapies in key regions will drive the global expansion of the Relapsed or Refractory Diffuse Large B-cell Lymphoma market over the forecast period.
Market Key Trends
Adoption of CAR T-cell therapy: Chimeric antigen receptor (CAR) T-cell therapy has emerged as a promising treatment approach for Relapsed or Refractory Diffuse Large B-cell Lymphoma Market patients. Yescarta and Kymriah have been approved by the FDA which is driving the adoption of this novel immunotherapy in clinical practice.
Porter’s Analysis
Threat of new entrants: High costs involved in R&D of new drugs and biologics pose significant barriers.
Bargaining power of buyers: Patients have limited treatment options but increasing awareness empowers patients to negotiate with treatment providers.
Bargaining power of suppliers: Few big pharmaceutical companies dominate the market for cancer drugs increasing their bargaining power over treatment providers.
Threat of new substitutes: Continued innovation in cancer treatment is expected to yield new treatment options over time.
Competitive rivalry: Intense competition between large pharmaceutical companies to develop novel therapies and gain market share.
Geographical Regions
North America currently holds the largest share of the relapsed or refractory diffuse large B-cell lymphoma market owing to high treatment costs and increasing adoption of novel therapies.
Asia Pacific is expected to register the fastest growth during the forecast period supported by rising healthcare investments, growing patient awareness, and expanding capabilities of regional healthcare systems.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
